Neonatal seizures associated with maternal hydroxyzine hydrochloride in late pregnancy.
This is the first report of a neonatal withdrawal syndrome associated with maternal hydroxyzine treatment (150 mg/day) confirmed by measurements of hydroxyzine plasma concentrations in the mother and infant after birth. Hydroxyzine plasma concentrations were measured by liquid chromatography-mass spectrometry. Neurological symptoms with low neonatal concentrations of hydroxyzine may be due to a withdrawal syndrome. According to previous observations and this case report, clinicians should be warned of this possible rare neurological complication of hydroxyzine in neonates born from long term treated mothers.
Serreau
Raphaël
R
Paediatric Pharmacology and Pharmacogenetic, Hôpital Robert debré, 48 boulevard Sérurier, Paris, France. raphael.serreau@rdb.aphp.fr
Komiha
Meriem
M
Blanc
Florence
F
Guillot
François
F
Jacqz-Aigrain
Evelyne
E
D000328:Adult; D005260:Female; D005312:Fetal Blood / Q000737:chemistry; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D006801:Humans; D006919:Hydroxyzine / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000139:chemically induced*; D008297:Male; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D012640:Seizures / Q000139:chemically induced*; D013375:Substance Withdrawal Syndrome / Q000209:etiology*
D006634:Histamine H1 Antagonists; D006919:Hydroxyzine